Design and rationale of the URGENT dyspnea study: An international, multicenter, prospective study

American Journal of Therapeutics

Volumn 15, Issue 4, 2008, Pages 299-303

  Pang, Peter S ^a   Tavares, Miguel ^b   Collins, Sean P ^c   Cleland, John G F ^d   Hollander, Judd ^e   Nieminen, Markku ^f   Miller, Chadwick ^g   Courtney, D Mark ^a   Kirk, J Douglas ^h   Masip, Josep ⁱ   Parkhomenko, Alexander ^j   Macarie, Cezar ^k   Peacock, W Frank ^l   Spinar, Jindrich ^m   Nowak, Richard ⁿ   Raev, Dimitar ^o   Storrow, Alan B ^p   Spisak, Vladimir ^q   Hamdy, Ahmed ^r   Mebazaa, Alexandre ^s   Gheorghiade, Mihai ^a   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF HULL   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HOSPITAL DOS DE MAIG   (Spain)

^j Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^k Institutul de Boli Cardiovasculare   (Romania)

^l LERNER RESEARCH INSTITUTE   (United States)

^m UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁿ HENRY FORD HEALTH SYSTEM   (United States)

^o Central Clinical Hospital   (Bulgaria)

^p VANDERBILT UNIVERSITY   (United States)

^q Hospitel Zilina   (Slovakia)

^r PDL BioPharma Inc   (United States)

^s HÔPITAL LARIBOISIÈRE   (France)

more..

Author keywords

Acute heart failure syndromes; Dyspnea; Emergency department

Indexed keywords

DIURETIC AGENT; INOTROPIC AGENT; MORPHINE; NITRATE; PLACEBO; VASOPRESSIN;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; EMERGENCY CARE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATIENT ASSESSMENT; PRIORITY JOURNAL; SITTING; SUPINE POSITION; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ACUTE DISEASE; ADOLESCENT; ADULT; HEART FAILURE; HOSPITALIZATION; METHODOLOGY; PATIENT SELECTION; PROSPECTIVE STUDY; TIME;

ACUTE DISEASE; ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; DYSPNEA; HEART FAILURE; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 51649097262     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31816b436e     Document Type: Article

References (21)

1. ADHERE Scientific Advisory Committee. Acute Decompensated Heart Failure National Registry (ADHERE®) Core Module Q1 2006 Final Cumulative National Benchmark Report. Mountain View, California: Scios Inc; 2006.
2. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287: 1531-1540.
3. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
4. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019.
5. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883-1891.
6. Teerlink JR, Massie B, Cleland J, et al. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure. Circulation. 2001;104:II-526. Abstract.
7. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287:1541-1547.
8. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Cardiac Failure, Addendum on Acute Cardiac Failure. London: EMEA, European Medicines Agency; 2004. CPMP/EWP/2986/03.
9. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958-3968.
10. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J. 2003;145(Suppl 2):S26-S33.
11. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297:1319-1331.
12. Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST Trials. JAMA. 2007;297: 1374-1376.
13. Gheorghiade M, Filippatos G, De Luca L, et al. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(Suppl 1): S3-S10.
14. Hill JA, Yancy CW, Abraham WT. Beyond diuretics: management of volume overload in acute heart failure syndromes. Am J Med. 2006;119(Suppl 1): S37-S44.
15. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med. 2006;119(Suppl 1):S26-S36.
16. Emerman C, DeMarco T, Constanzo M, et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail. 2004;10: S116. Abstract.
17. Hugli O, Braun JE, Kim S, et al. United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am J Cardiol. 2005;96:1537-1542.
18. Peacock Iv WF, Fonarow GC, Emerman CL, et al. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. May 4 2006;107:44-51.
19. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24: 442-463.
20. Peacock WF, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005;29: 243-252.
21. Peacock WF, Young J, Collins S, et al. Heart failure observation units: optimizing care. Ann Emerg Med. 2006; 47:22-33.